BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10073723)

  • 21. Analysis of recombinant group B streptococcal protein ScaAB and evaluation of its immunogenicity.
    Vorobieva EI; Meringova LF; Leontieva GF; Grabovskaya KB; Suvorov AN
    Folia Microbiol (Praha); 2005; 50(2):172-6. PubMed ID: 16110924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
    Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
    J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Pinel J; Kasper DL
    J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC; Paoletti LC; Tai JY; Kasper DL
    J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The opsonic antibody response of female rats to type III group B streptococcal immunization: a model for maternal immunity.
    Heiman HS; Weisman LE
    Vet Immunol Immunopathol; 1990 Jan; 24(1):79-89. PubMed ID: 2180204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
    Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
    ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.
    Brodeur BR; Boyer M; Charlebois I; Hamel J; Couture F; Rioux CR; Martin D
    Infect Immun; 2000 Oct; 68(10):5610-8. PubMed ID: 10992461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
    Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Safe and Stable Neonatal Vaccine Targeting GAPDH Confers Protection against Group B Streptococcus Infections in Adult Susceptible Mice.
    Alves J; Madureira P; Baltazar MT; Barros L; Oliveira L; Dinis-Oliveira RJ; Andrade EB; Ribeiro A; Vieira LM; Trieu-Cuot P; Duarte JA; Carvalho F; Ferreira P
    PLoS One; 2015; 10(12):e0144196. PubMed ID: 26673420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a universal Group B streptococcus vaccine by multiple genome screen.
    Maione D; Margarit I; Rinaudo CD; Masignani V; Mora M; Scarselli M; Tettelin H; Brettoni C; Iacobini ET; Rosini R; D'Agostino N; Miorin L; Buccato S; Mariani M; Galli G; Nogarotto R; Nardi-Dei V; Vegni F; Fraser C; Mancuso G; Teti G; Madoff LC; Paoletti LC; Rappuoli R; Kasper DL; Telford JL; Grandi G
    Science; 2005 Jul; 309(5731):148-50. PubMed ID: 15994562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group B streptococcal vaccines.
    Baker CJ; Kasper DL
    Rev Infect Dis; 1985; 7(4):458-67. PubMed ID: 3898306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological markers of the R4 protein of Streptococcus agalactiae.
    Maeland JA; Bevanger L; Lyng RV
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1305-10. PubMed ID: 16275945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein.
    Madoff LC; Michel JL; Gong EW; Rodewald AK; Kasper DL
    Infect Immun; 1992 Dec; 60(12):4989-94. PubMed ID: 1452329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
    Leroux-Roels G; Maes C; Willekens J; De Boever F; de Rooij R; Martell L; Bedell L; Wittke F; Slobod K; Dull P
    Vaccine; 2016 Apr; 34(15):1786-91. PubMed ID: 26928074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural acquired group B Streptococcus capsular polysaccharide and surface protein antibodies in HIV-infected and HIV-uninfected children.
    Dzanibe S; Adrian PV; Kimaro Mlacha SZ; Madhi SA
    Vaccine; 2016 Oct; 34(44):5217-5224. PubMed ID: 27663669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein.
    Martin D; Rioux S; Gagnon E; Boyer M; Hamel J; Charland N; Brodeur BR
    Infect Immun; 2002 Sep; 70(9):4897-901. PubMed ID: 12183534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
    J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.
    Maruggi G; Chiarot E; Giovani C; Buccato S; Bonacci S; Frigimelica E; Margarit I; Geall A; Bensi G; Maione D
    Vaccine; 2017 Jan; 35(2):361-368. PubMed ID: 27939014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.